C V Starr & Co. Inc. Makes New Investment in Celularity, Inc. $CELU

C V Starr & Co. Inc. acquired a new stake in Celularity, Inc. (NASDAQ:CELU) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 764,069 shares of the company’s stock, valued at approximately $1,582,000. Celularity makes up 0.8% of C V Starr & Co. Inc.’s portfolio, making the stock its 4th largest holding.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Acadian Asset Management LLC bought a new position in shares of Celularity in the first quarter valued at approximately $34,000. XTX Topco Ltd boosted its holdings in shares of Celularity by 106.4% during the 2nd quarter. XTX Topco Ltd now owns 21,452 shares of the company’s stock worth $42,000 after buying an additional 11,057 shares during the period. Bank of America Corp DE grew its stake in Celularity by 1,538.1% in the 2nd quarter. Bank of America Corp DE now owns 37,300 shares of the company’s stock valued at $73,000 after buying an additional 35,023 shares during the last quarter. Vanguard Group Inc. raised its holdings in Celularity by 35.3% in the 3rd quarter. Vanguard Group Inc. now owns 676,650 shares of the company’s stock worth $1,401,000 after acquiring an additional 176,518 shares during the period. Finally, Geode Capital Management LLC lifted its position in Celularity by 15.0% during the 4th quarter. Geode Capital Management LLC now owns 160,190 shares of the company’s stock worth $178,000 after acquiring an additional 20,876 shares during the last quarter. 19.02% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered Celularity from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, August 5th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $6.00.

Celularity Stock Performance

Shares of CELU stock opened at $0.80 on Friday. The firm has a fifty day moving average of $0.72 and a 200-day moving average of $0.99. The stock has a market cap of $23.16 million, a price-to-earnings ratio of -0.24 and a beta of 0.54. Celularity, Inc. has a 52-week low of $0.56 and a 52-week high of $4.01.

Celularity Profile

Celularity, Inc is a clinical-stage biotechnology company focused on the development of allogeneic, placenta-derived cell therapies and exosome-based biologics for oncology, regenerative medicine and immune-driven conditions. Utilizing a proprietary platform that harnesses the unique properties of postpartum placental cells, the company aims to create off-the-shelf therapies that can be administered without the need for tissue matching or conditioning regimens.

The company’s pipeline includes a range of natural killer (NK) cell products, mesenchymal-like placental stromal cells and exosome formulations designed to modulate inflammatory responses and target tumor cells.